×
About 1,115 results

ALLMedicine™ Pustular Psoriasis Center

Research & Reviews  347 results

A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient wi...
https://doi.org/10.1111/1756-185X.14392
International Journal of Rheumatic Diseases; Karaalioğlu B, Yıldırım F et. al.

Aug 4th, 2022 - Palmoplantar pustular psoriasis (PPP) is a rare clinical form of psoriasis. It is usually seen on the palms and soles, and affects patients' quality of life. In most cases, topical or systemic treatments are not sufficiently effective, so manageme...

Psoriasis Treatment & Management
http://emedicine.medscape.com/article/1943419-treatment

Aug 3rd, 2022 - Approach Considerations Management of psoriasis may involve topical and systemic medication, phototherapy, stress reduction, climatotherapy, and various adjuncts such as sunshine, moisturizers, salicylic acid, and other keratolytics such as urea. ...

A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130
https://clinicaltrials.gov/ct2/show/NCT03886246

Jul 26th, 2022 - To evaluate the long-term safety and efficacy of BI 655130 in patients with GPP, who have completed previous BI 655130 trials and are qualified for entry in this trial

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04399837

Jul 26th, 2022 - This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost cle...

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
https://clinicaltrials.gov/ct2/show/NCT05200247

Jul 26th, 2022 - This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment optio...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  31 results

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04399837

Jul 26th, 2022 - This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost cle...

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
https://clinicaltrials.gov/ct2/show/NCT05200247

Jul 26th, 2022 - This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment optio...

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
https://clinicaltrials.gov/ct2/show/NCT05239039

Jul 26th, 2022 - This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment opt...

A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130
https://clinicaltrials.gov/ct2/show/NCT03886246

Jul 26th, 2022 - To evaluate the long-term safety and efficacy of BI 655130 in patients with GPP, who have completed previous BI 655130 trials and are qualified for entry in this trial

A Study of Guselkumab in Participants With Active Lupus Nephritis
https://clinicaltrials.gov/ct2/show/NCT04376827

Jul 15th, 2022 - Guselkumab is a monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent activat...

see more →

News  57 results

Large study reaffirms rare risk of TNF inhibitor–induced psoriasis in patients with RA, IBD
https://www.mdedge.com/dermatology/article/256146/psoriasis/large-study-reaffirms-rare-risk-tnf-inhibitor-induced-psoriasis
Jeff Craven

Jul 11th, 2022 - Patients with rheumatoid arthritis or inflammatory bowel disease (IBD) taking a tumor necrosis factor–alpha inhibitor (TNFi) have about a two-fold higher risk of developing psoriasis, compared with patients receiving conventional treatment, accord.

Cohort Study Evaluates Risk of TNF Inhibitor–Induced Psoriasis in Patients With RA, IBD
https://www.medscape.com/viewarticle/976899

Jul 11th, 2022 - Patients with rheumatoid arthritis or inflammatory bowel disease (IBD) taking a tumor necrosis factor–alpha inhibitor (TNFi) have about a two-fold higher risk of developing psoriasis, compared with patients receiving conventional treatment, accord...

Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
https://www.mdedge.com/dermatology/article/250395/psoriasis/case-series-show-no-consensus-treatment-palmoplantar-pustulosis
Jeff Craven

Jan 4th, 2022 - A wide range of treatments are being used to manage patients with palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP), according to the results of two case series that evaluated the characteristics and course of the disease in p.

Case Series Show No Consensus on Treatment for Palmoplantar Pustulosis, Generalized Pustular Psoriasis
https://www.medscape.com/viewarticle/965994

Jan 4th, 2022 - A wide range of treatments are being used to manage patients with palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP), according to the results of two case series that evaluated the characteristics and course of the disease in p...

Spesolimab speeds lesion clearance in generalized pustular psoriasis
https://www.mdedge.com/dermatology/article/250261/psoriasis/spesolimab-speeds-lesion-clearance-generalized-pustular
Heidi Splete

Dec 27th, 2021 - Spesolimab, a humanized, anti–interleukin-36 receptor monoclonal antibody, was associated with rapid improvement in pustules during flares, in a phase 2 study of 53 adults with generalized pustular psoriasis (GPP). GPP is a life-threatening skin c.

see more →

Patient Education  2 results see all →